Publications
CER Interview with Dr. William W. Li
| Type: | Podcast |
| Date: | December 7, 2011 |
| Related Topics: | Aging Research, Drug Development, Drug Safety, Medical Innovation, Policy, Research, Vision Loss |
William W. Li, MD resident, Medical Director, and Co-founder of the Angiogenesis Foundation, has been changing the face of modern Medicine for 25 years, by tackling a "common denominator" of disease called angiogenesis, or new blood vessel growth. Trained by research pioneer Dr. Judah Folkman, Dr. Li is leading national and international efforts to bring forth revolutionary new treatments for cancer, diabetes, blindness, and heart disease that restore the body's normal balance of blood vessels. Through the Foundation, he has created a unique model for speeding medical advances by driving collaborations between scientists, clinicians, industry, regulators, payers, and patients. A major current focus of Dr. Li is aligning the goals of medical innovation and comparative effectiveness research and emerging health policy.
A native of Pittsburgh, Dr. Li received his undergraduate degree from Harvard College, and his medical degree from the University of Pittsburgh School of Medicine. He completed his clinical training in Internal Medicine at the Massachusetts General Hospital in Boston. Dr. Li has served on the faculties of Harvard Medical School, and Tufts University School of Veterinary Medicine, and is currently a Visiting Assistant Professor of Medicine at Dartmouth Medical School. His work has been published in Science, The New England Journal of Medicine, The Lancet, and other leading peer-reviewed journals. Dr. Li has been a speaker at the TED Conference, and is a member of the Clinton Global Initiative.
Tweet
A native of Pittsburgh, Dr. Li received his undergraduate degree from Harvard College, and his medical degree from the University of Pittsburgh School of Medicine. He completed his clinical training in Internal Medicine at the Massachusetts General Hospital in Boston. Dr. Li has served on the faculties of Harvard Medical School, and Tufts University School of Veterinary Medicine, and is currently a Visiting Assistant Professor of Medicine at Dartmouth Medical School. His work has been published in Science, The New England Journal of Medicine, The Lancet, and other leading peer-reviewed journals. Dr. Li has been a speaker at the TED Conference, and is a member of the Clinton Global Initiative.
“A the end of the day, CATT represents one early milestone, and an important study that’s going to be used as a case study for comparative effectiveness, or CER research. And one of the more interesting policy questions is, since the NIH provided funding for the CATT study, should the NIH be funding even more CER studies.”
Tweet
This podcast series provides expert reactions to the CATT trial data in terms of what it will mean for wAMD patients and professionals, and its potential impact on future trials, policies and innovation.
To listen to interviews on this topic with other experts, click here.
To listen to interviews on this topic with other experts, click here.
Living Longer and Loving It!
Sign up for the Alliance's quarterly newsletter and get timely information on advancements in science, treatment, and health policy that help you "Live Longer and Love It."